This study aims to evaluate and analyze the applications and limitations of the available noninvasive markers in patients with chronic liver disease. Cost pressures and recognitions of limitations of liver biopsy have led to increasing need for noninvasive tests to assess both the stage of liver fibrosis and more importantly the rate of progression of fibrogenic chronic liver disease. There are 2 groups of noninvasive methodologies for evaluations of hepatic fibrosis; serum markers (direct, indirect), liver imaging techniques. In this study, we focused this metaanalysis on APRI and fibroscan.